In molecular GBM treated with alkylating chemotherapy including radiochemotherapy, MGMT promotor methylation was associated with improved progression free survival (statistical significance for overall survival was not reached in patients with molecular GBM, potentially due to the relatively small sample size). This evidence concerns the gene MGMT and glioblastoma.